eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2024
vol. 28
 
Share:
Send email
Share:
Original paper

A cohort of long-surviving patients affected by small and medium uveal melanoma treated with ruthenium-106 plaque brachytherapy

Concetta Laliscia
1
,
Franco Perrone
2
,
Francesca Guido
3
,
Federica Cresti
3
,
Taiusha Fuentes
1
,
Fabiola Paiar
1
,
Guglielmo Pellegrini
2
,
Federica Genovesi Ebert
2

  1. Department of New Technologies and Translational Research, Division of Radiation Oncology, University Hospital of Pisa, Pisa, Italy
  2. Department of Medical Physics, Division of Medical Physics, University Hospital of Pisa, Pisa, Italy
  3. Department of Ophthalmic Surgery, Division of Ophthalmic Surgery, University Hospital of Pisa, Pisa, Italy
Contemp Oncol (Pozn) 2024; 28 (4): 318–325
DOI: https://doi.org/10.5114/wo.2024.146992
Online publish date: 2025/01/15
Article file
- A cohort of long-surviving.pdf  [0.09 MB]
Get citation
 
PlumX metrics:
 
1. Mahendraraj K, Lau CSM, Lee I, Chamberlain RS. Trends in incidence, survival, and management of uveal melanoma: a population-based study of 7516 patients from the surveillance, epidemiology, and end results database (1973-2012). Clin Ophthalmol 2016; 10: 2113-2119.
2. Tóth G, Muzsik B, Szajkó A, et al. Incidence and mortality of uveal melanoma in Hungary: a nationwide study. Cancers (Basel) 2024; 16: 931. DOI: 10.3390/cancers16050931.
3. Wu M, Yavuzyigitoglu S, Brosens E, Ramdas WD, Kiliç E; Rotterdam Ocular Melanoma Study Group (ROMS). Worldwide incidence of ocular melanoma and correlation with pigmentation-related risk factors. Investig Ophthalmol Vis Sci 2023; 64: 45. DOI: 10.1167/iovs. 64.13.45.
4. Collaborative Ocular Melanoma Study Group. Clinical Trial Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 2001; 119: 670-676.
5. Liu XL, Run-Hua Z, Pan JX, Li ZJ, Yu L, Li YL. Emerging therapeutic strategies for metastatic uveal melanoma: targeting driver mutations. Pigment Cell Melanoma Res 2024; 37: 411-425.
6. Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol 2009; 127: 989-998.
7. Szalai E, Jiang Y, van Poppelen NM, et al. Association of uveal melanoma metastatic rate with stochastic mutation rate and type of mutation. JAMA Ophthalmol 2018; 136: 1115-1120.
8. Gelmi MC, Bas Z, Malkani K, Ganguly A, Shields CL, Jager MJ. Adding the cancer genome atlas chromosome classes to American Joint Committee on Cancer system offers more precise prognostication in uveal melanoma. Ophthalmology 2022; 129: 431-437.
9. Laliscia C, Genovesi-Ebert F, Perrone F, et al. Photon-based high-dose single-fraction radiosurgery, an effective treatment modality for large and posterior uveal melanoma. Anticancer Res 2022; 42: 1965-1972.
10. Shields JA, Shields CL. Management of posterior uveal melanoma: past, present, and future: the 2014 Charles L. Schepens lecture. Ophthalmology 2015; 122: 414-428.
11. Margo CE. The collaborative ocular melanoma study: an overview. Cancer Control 2004; 11: 304-309.
12. Diener-West M, Earle JD, Fine SL, et al.; Collaborative Ocular Mela­noma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS report no. 18. Arch Ophthalmol 2001; 119: 969-982.
13. Moore RF. Choroidal sarcoma treated by the intraocular insertion of radon seeds. Br J Ophthalmol 1930; 14: 145-152.
14. Grech Fonk L, Ferreira TA, Webb AG, Luyten GPM, Beenakker JM. The economic value of MR-imaging for uveal melanoma. Clin Ophthalmol 2020; 14: 1135-1143.
15. Foti PV, Travali M, Farina R, et al. Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part II: treatment indications and complications. Insights Imaging 2021; 12: 67. DOI: 10.1186/s13244-021-01001-w.
16. American Brachytherapy Society – Ophthalmic Oncology Task Force. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy 2014; 13: 1-14.
17. Savino G, Piccinni F, Pagliara MM, et al. Multidisciplinary ocular and periocular cancers meetings: implementation in a tertiary referral center and analysis over a 12-months period. BMC Ophthalmol 2022; 22: 497. DOI: 10.1186/s12886-022-02694-3.
18. Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther 2018; 18: 775-784.
19. De Brabandere M, Placidi E, Siebert FA, et al. GEC-ESTRO survey of 106Ru eye applicator practice for ocular melanoma – physicist survey. Radiother Oncol 2024; 193: 110114. DOI: 10.1016/j.radonc. 2024.110114.
20. Stöckel E, Eichmann M, Flühs D, et al. Dose distributions and treatment margins in ocular brachytherapy with 106Ru eye plaques. Ocul Oncol Pathol 2018; 4: 122-128.
21. Mirshahi R, Sedaghat A, Jaberi R, Azma Z, Mazloumi M, Naseri­pour M. Ruthenium-106 plaque radiotherapy for uveal melanoma: analysis of tumor dimension and location on anatomical and functional results. BMC Ophthalmol 2022; 22: 309. DOI: 10.1186/s12886-022-02521-9.
22. Aziz HA, Al Zahrani YA, Bena J, et al. Episcleral brachytherapy of uveal melanoma: role of intraoperative echographic confirmation. Br J Ophthalmol 2017; 101: 747-751.
23. NCI. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v.5.0). Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. 2017.
24. Fang R, Wang H, Li Y, Liu YM, Wei WB. Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy. BMC Ophthalmol 2021; 21: 137. DOI: 10.1186/s12886-021-01898-3.
25. Fionda B, Pagliara MM, Lancellotta V, et al. Radiological and clinical findings in uveal melanoma treated by plaque interventional radiotherapy (brachytherapy): visual atlas and literature review on response assessment. J Contemp Brachytherapy 2022; 14: 96-106.
26. Brewington BY, Shao YF, Davidorf FH, Cebulla CM. Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 2018; 12: 925-934.
27. Egger E , Schalenbourg A, Zografos L, et al. Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys 2001; 51: 138-147.
28. Seibel I, Cordini D, Rehak M, et al. Local recurrence after primary proton beam therapy in uveal melanoma: risk factors, retreatment approaches, and outcome. Am J Ophthalmol 2015; 160: 628-636.
29. Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44: 4651-4659.
30. Liu X, Liu C, Shang Y, Yang L, Tan F, Lv Y. Prognostic factors and nomograms for overall and cancer-specific survival of patients with uveal melanoma without metastases: a SEER analysis of 4119 cases. J Ophthalmol 2022; 2022: 1874336. DOI: 10.1155/ 2022/1874336.
31. Gelmi MC, Jager MJ. Uveal melanoma: current evidence on prognosis, treatment and potential developments. Asia Pac J Ophthalmol (Phila) 2024; 13: 100060. DOI: 10.1016/j.apjo.2024.100060.
32. Perri P, Fiorica F, D’Angelo S, et al. Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: a mono-institutional experience. Eur Rev Med Pharmacol Sci 2012; 16: 1919-1924.
33. Pagliara MM, Tagliaferri L, Lenkowicz J, et al. AVATAR: analysis for visual acuity prediction after eye interventional radiotherapy. In Vivo 2020; 34: 381-387.
34. Cennamo G, Montorio D, D’ Andrea L, et al. Long-term outcomes in uveal melanoma after ruthenium-106 brachytherapy. Front Oncol 2022; 11: 754108. DOI: 10.3389/fonc.2021.754108.
35. Messineo D, Barile G, Morrone S, et al. Meta-analysis on the utility of radiotherapy for the treatment of ocular melanoma. Clin Ter 2020; 170: e89-e98. DOI: 10.7417/CT.2020.2195.
36. Fionda B, Pagliara MM, Chyrek AJ, et al. Ocular brachytherapy (interventional radiotherapy): preserving the vision. Clin Oncol (R Coll Radiol) 2023; 35: e445-e452. DOI: 10.1016/j.clon.2023.01.021.
Copyright: © 2025 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.